Rare case of hemangiopericytoma responds to sunitinib

Translational Research

Volumn 151, Issue 3, 2008, Pages 129-133

  Mulamalla, Keerthi ^a   Truskinovsky, Alexander M ^a   Dudek, Arkadiusz Z ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLATELET DERIVED GROWTH FACTOR RECEPTOR; SUNITINIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; BONE RESECTION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMUR; HEMANGIOPERICYTOMA; HUMAN; MALE; MAXILLARY SINUS; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TONGUE ULCER; TUMOR RECURRENCE;

EID: 39149100614     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2007.12.007     Document Type: Article

References (16)

1. Millman B., Brett D., and Vrabec D.P. Sinonasal hemangiopericytoma. Ear, Nose Throat J 73 (1994) 680-682 687
2. Palacios E., Restrepo S., Mastrogiovanni L., Lorusso G.D., and Rojas R. Sinonasal hemangiopericytomas: clinicopathologic and imaging findings. Ear, Nose Throat J 84 (2005) 99-102
3. Reiner S.A., Siegel G.J., Clark K.F., and Min K.W. Hemangiopericytoma of the nasal cavity. Rhinology 28 (1990) 129-136
4. Coindre J.M., Terrier P., Guillou L., et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91 (2001) 1914-1926
5. Weber W., Henkes H., Metz K.A., Berg-Dammer E., and Kühne D. Haemangiopericytoma of the nasal cavity. Neuroradiology 43 (2001) 183-186
6. Mena H., Ribus J.L., Pezzesshkpour G.H., Cowan D.N., and Parisi J.E. Hemangiopericytoma of the central nervous system: a review of 94 cases. Hum Pathol 22 (1991) 84-91
7. Guthrie B.L., Ebersold M.J., Scheithauer B.W., and Shaw E.G. Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery 25 (1989) 514-522
8. Fatusi O.A., Owotade F.J., and Ojo O.S. Maxillary haemangiopericytoma: a case report. West Afr J Med 23 (2004) 180-184
9. Combs S.E., Thilmann C., Debus J., and Schulz-Ertner D. Precision radiotherapy for hemangiopericytomas of the central nervous system. Cancer 104 (2005) 2457-2465
10. Hansen T., Gaumann A., Ghalibafian M., Hoferlin A., Heintz A., and Kirkpatrick C.J. Haemangiopericytoma of the thyroid gland in combination with Hashimoto's disease. Virchows Arch 445 (2004) 315-319
11. Hatva E., Bohling T., Jaaskelainen J., Persico M.G., Haltia M., and Alitalo K. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol 148 (1996) 763-775
12. Fletcher C.D. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 48 (2006) 3-12
13. Patyna S., Laird A.D., Mendel D.B., et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 5 (2006) 1774-1782
14. Gale N.W., and Yancopoulos G.D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13 (1999) 1055-1066
15. Cherrington J.M., Strawn L.M., and Shawver L.K. New paradigms for the treatment of cancer; the role of anti-angiogenesis agents. In: Klein G., and Vande Woude G.F. (Eds). Advances in cancer research vol. 79 (2000), Academic Press, San Diego, Calif 1-38
16. Sun L., Liang C., Shirazian S., et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 7 (2003) 1116-1119